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Abstract
Background: Cerebral venous sinus thrombosis (CVST) has been described after vaccination against 
SARS-CoV-2. We report clinical characteristics of 213 post-vaccination CVST cases notified to the 
European Medicines Agency (EMA).
Methods: Data on Adverse Drug Reactions after SARS-CoV-2 vaccination notified until 8 April 2021 under 
the Medical Dictionary for Regulatory Activities Term ‘Central nervous system vascular disorders’ were 
obtained from the EudraVigilance database. We compared post-vaccination CVST to 100 European 
patients with CVST from before the COVID-19 pandemic derived from the International CVST Consortium.
Results: We identified 213 CVST cases: 187 after AstraZeneca/Oxford (ChAdOx1 nCov-19), vaccination 
and 26 after a mRNA vaccine (25 Pfizer/BioNTech, BNT162b2  and 1 Moderna, mRNA-1273). 
Thrombocytopenia was reported in 107/187 CVST cases (57%, 95%CI 50-64%) in the ChAdOx1 nCov-19 
group, in none in the mRNA vaccine group (0%, 95%CI 0-13%), and in 7/100 (7%, 95%CI 3-14%) in the 
pre-COVID-19 group. In the ChAdOx1 nCov-19 group, there were 39 (21%) reported COVID-19 PCR tests 
performed within 30 days of CVST symptom onset, and all were negative. Of the 117 patients with a 
reported outcome in the ChAdOx1 nCov-19 group, 44 (38%, 95%CI 29-47%) had died, compared to 2/10 
(20%, 95%CI 6-51%) in the mRNA vaccine group and 3/100 (3%, 95%CI 1-8%) in the pre-COVID-19 
group. Mortality among patients with thrombocytopenia in the ChAdOx1 nCov-19 group was 49% (95%CI 
39-60%). 
Conclusions: CVST occurring after ChAdOx1 nCov-19 vaccination has a clinical profile distinct from CVST 
unrelated to vaccination. Only CVST after ChAdOx1 nCov-19 was associated with thrombocytopenia.
Keywords: COVID-19 vaccine,  CVST, thrombocytopenia, EMA
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Introduction
Vaccination against SARS-CoV-2 has been initiated at an impressive speed to lower the global burden of 
the COVID-19 pandemic. By April 2021, four vaccines were licensed by the European Medicines Agency 
(EMA) and are currently in use in Europe: a recombinant chimpanzee adenoviral vector from Astra-
Zeneca/Oxford (ChAdOx1 nCov-19), a recombinant adenovirus type 26 vector from 
Janssen/Johnson&Johnson (Ad26.COV2.S) and two messenger RNA-based vaccines, one from 
Pfizer/BioNTech (BNT162b2) and one from Moderna (mRNA-1273) (1). After vaccination of millions of 
individuals, several patients were reported who developed cerebral venous sinus thrombosis (CVST) or 
other thrombotic events, frequently in combination with thrombocytopenia, within 28 days of vaccination (2-
6). This condition has been termed vaccine-induced immune thrombotic thrombocytopenia (VITT) and 
appears to be related to the ChAdOx1 nCov-19 and Ad26.COV2.S vaccines (2, 4, 7). 
The number of published post-SARS-CoV-2-vaccination CVST cases is small and there is a possibility of 
selective reporting of patients with VITT. Also, characteristics of patients who developed CVST after SARS-
CoV-2 vaccination have not yet been compared to patients with CVST from before the COVID-19 
pandemic. Here, we report clinical data of patients with CVST notified to EMA after SARS-CoV-2-
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Methods
Data selection
The European Medicine Agency (EMA) granted the authors research access to the EudraVigilance 
database (8). EMA is the official institution of the European Economic Area (EEA) that regulates all drug-
related activities within the European Union and one of its duties is to collect data on Adverse Drug 
Reactions (ADRs) (9, 10). EudraVigilance is a passive pharmacovigilance system hosted and maintained 
by EMA in which all reported suspected ADRs are collected from the marketing authorisation holders and 
national competent authorities (10). Following approval by EMA of a formal request by the authors 
(submitted 1 April 2021), a level 2A  output was provided of Individual Case Safety Report (ICSR) data with 
a Medical Dictionary for Regulatory Activities High Level Group Term (MedDRA HLGT, version 24.0) 
‘Central nervous system vascular disorders’, for which suspected ADRs were collected according to the 
European legislation, for each of the four SARS-CoV-2 vaccines approved by EMA (ChAdOx1 nCov-19, 
BNT162b2, mRNA-1273, and Ad26.COV2.S). The data extracted include the suspected adverse events 
reported to the EudraVigilance post-marketing module between 24 December 2020 and 8 April 2021 from 
the EEA and the United Kingdom, as well as any suspected serious ADR’s within and outside of the EEA 
(8) .
Cases with the following “Reaction Preferred Terms” (RCPT) of the Medical Dictionary for Regulatory 
Activities were considered to have CVST: “cerebral venous thrombosis”, “cerebral venous sinus 
thrombosis”, “jugular vein thrombosis”, “superior sagittal sinus thrombosis”, “transverse sinus thrombosis” 
and “cavernous sinus thrombosis”. In addition, we screened cases with a RCPT that could potentially 
indicate CVST (see Table S1 in the appendix). Clinical data of each case with one of the RCPTs which 
could indicate a CVST were independently screened by two of three investigators (KK, MSK, and TH), 
using information from the reported Data Elements available (see Table S2 in the appendix). Cases that 
were marked as “potential CVST” by at least one of the investigators were adjudicated by a senior vascular 
neurologist (JMC), who made the final decision on whether or not to classify the case as CVST. After 
identification of the CVST cases, duplicates and cases that were reported from countries outside the 
European continent were excluded. 
We considered the following variables as traditional CVST risk factors: cancer, hormone replacement 
therapy or oral contraceptive use, genetic thrombophilia and any concomitant infection. Thrombocytopenia 
was defined as a platelet count of <150 x103/µL. Cases were considered to have thrombocytopenia if 
platelet counts <150 x103/µL were reported in the “Result Unstructured Data” (F.r.3.4) (see Table S2 in the 
appendix) or if there was RCPT “thrombocytopenia” reported.
We compared CVST reported in patients who received an adenovirus based vaccine (ChAdOx1 nCov-19 
and Ad26.COV2.S) to patients who received a mRNA vaccine (BNT162b2 and mRNA-1273). However, 
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during the study period, this vaccine was disregarded from the analysis. We additionally compared post-
vaccination CVST cases to a control group of CVST patients diagnosed prior to the COVID-19 pandemic. 
Data for this control sample were derived from the international CVST consortium, which is an academic 
collaboration established in 2015 with the aim to perform clinical research on CVST (11-14). CVST patients 
from three participating European hospitals (see Table S4 in the appendix) – all with symptom onset 
between 1 January 2015 and 31 December 2017 were used as a control sample. Each centre obtained 
permission from their ethical review board for the collection of observational data. Written patient informed 
consent was obtained if required under applicable national laws.
Statistical analysis
We performed a descriptive analysis, calculating median and interquartile range for continuous variables, 
and counts and percentages for categorical variables. We calculated 95% confidence intervals (95%CI) for 
the following variables that were hypothesized to be different between the cases after adenovirus-based 
vaccination and the two other groups: thrombocytopenia, concomitant venous thromboembolic events 
(VTE), and mortality. Confidence intervals were calculated using Wilson’s method using the Hmisc package 
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Results
Out of 2517 individual cases with at least one neurovascular ADR recorded in the EudraVigilance 
database, we identified 213 CVST cases from 18 European countries (Figure 1). Of these, 187 occurred 
after ChAdOx1 nCov-19 vaccination and 26 after vaccination with a mRNA vaccine (25 BNT162b2 and 1 
mRNA-1273). In the control group there were 100 pre-COVID-19 CVST patients from the three European 
hospitals with symptom onset between 1 January 2015 and 31 December 2017. 
Median age was 46 (IQR 32-56), 56 (IQR 36-81), and 45 (IQR34-55) for the ChAdOx1 nCov-19, mRNA 
vaccine, and pre-COVID-19 groups, respectively. In the ChAdOx1 nCov-19 vaccine, mRNA vaccine, and 
pre-COVID-19 groups, there were 138 (75%), 20 (77%) and 66 (66%) women (Table 1). Median interval 
between first reported administration of SARS-CoV-2 vaccine and CVST symptom onset was 9 days (IQR 
5-13) in the ChAdOx1 nCov-19 group and 7 days (IQR 2-21) in the mRNA vaccine group. In the mRNA 
vaccine group, there were two patients who developed CVST 2 and 13 days after the second vaccination 
with BNT162b2 vaccine. 
A traditional CVST risk factor was reported in 20 (11%) and 4 (15%) cases in the ChAdOx1 nCov-19 and 
mRNA vaccine groups, respectively, whereas a CVST risk factor was identified in 64 (64%) patients in the 
pre-COVID-19 cohort group (Table 1). Among patients with thrombocytopenia in the ChAdOx1 nCov-19 
group, 10 (9%) had an additional risk factor reported (see Table S3 in the appendix).
Thrombocytopenia was reported in 107/187 cases (57%, 95%CI 50-64%) in the ChAdOx1 nCov-19 group, 
none in the mRNA vaccine group (95%CI 0-13%), and 7/100 (7%, 95%CI 3-14%) in the pre-COVID-19 
CVST group. Among patients with thrombocytopenia in the ChAdOx1 nCov-19 vaccine group, the median 
of the lowest reported platelet count was 31x103/µL (IQR 17-64, reported in 57/107 cases, 53%). 
Antibodies against platelet factor 4 were reported to be present in 15 cases in the ChAdOx1 nCov-19 group 
and in none in the mRNA vaccine group. There was no information on the number of patients tested for 
these antibodies.
In 22 patients (12%, 95%CI 8-17%) in the ChAdOx1 nCov-19 vaccine group a concomitant VTE in addition 
to CVST was reported, compared to none in the mRNA vaccine group (95%CI 0-13%) and 9 (9%, 95%CI 
5-16%) in the pre-COVID-19 group (Table 1). Of the 107 patients with thrombocytopenia in the ChAdOx1 
nCov-19 vaccine group, a concomitant VTE was reported in 19 (18%, 95%CI 12-26%) (see Table S3 in the 
appendix). 
A COVID-19 PCR test performed within 30 days from CVST symptom onset was reported in 39 (21%) 
cases in the ChAdOx1 nCov-19 vaccine group and in 6 (23%) in the mRNA vaccine group (Table 1). All 
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Of the 117 patients with a reported outcome in the ChAdOx1 nCov-19 vaccine group, 44 (38%, 95%CI 29-
47%) had died, compared to 2/10 (20%, 95%CI 6-51%) in the mRNA vaccine group and 3 (3%, 95%CI 1-
8%) in the pre-COVID-19 group. Among patients with thrombocytopenia in the ChAdOx1 nCov-19 vaccine 
group, 39/79 (49%, 95%CI 39-60%) patients with reported outcome died (see Table S3 in the appendix). 
Discussion
Using the EMA pharmacovigilance database and pre-COVID-19 CVST cases as a historical control group, 
we found that CVST reported after ChAdOx1 nCov-19 vaccination: (1) was notified more frequently than 
after the BNT162b2 and mRNA-1273 vaccines; (2) was associated in approximately half of patients with 
thrombocytopenia, with no thrombocytopenia reported for any patient following a mRNA vaccine; (3) was 
associated with positive anti-platelet factor 4 antibodies in some patients; (4) was accompanied in 1/8 
patients by other concomitant venous thrombotic events; (5) was associated with a high mortality rate, both 
when compared to CVST after mRNA vaccines or historical CVST controls, and (6) was infrequently 
associated with traditional CVST risk factors, which were present in two thirds of historical CVST controls. 
The confirmation that CVST arising after vaccination with the ChAdOx1 nCov-19 vaccine has distinct 
features further supports causality in this association, together with the consistent temporal sequence, and 
the identification of a putative pathophysiological mechanism (2-4).
Nevertheless, investigations for potential alternate causes are necessary to establish causality. COVID-19 
itself is associated with an increased risk of CVST (15, 16), and therefore the hypothesis of mild or 
undiagnosed SARS-CoV-2 infection has been suggested as a possible contributing factor for the post-
vaccination CVST cases. However, the current data make this hypothesis unlikely, since none of the 
patients with post-vaccination CVST tested positive for SARS-CoV-2 infection.
The features of CVST occurring after the mRNA vaccines should also be noted. Besides the lower 
frequency, we found no differences in the clinical profile when compared with historical controls. This 
suggests absence of an association, as CVST can occur by chance in the month following vaccination due 
to the background incidence. CVST can occur by chance either in association with any of the established 
risk factors or in the absence of any identified precipitant for CVST, as it has been previously described in 
about 15% of patients in the pre-COVID-19 era (17).
Another important finding was the identification of CVST in 21 subjects (of whom 13 had thrombocytopenia) 
above the age of 60 after the ChAdOx1 nCov-19 vaccine. Although this is somehow in disagreement to 
past reports (2, 3), it should be noted that because of the small sample size and absent denominator, no 
robust conclusions regarding incidence by age groups can be drawn, especially since the age and sex 
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European countries the ChAdOx1 nCov-19 vaccine was initially used predominantly in persons under 65, 
whereas the mRNA vaccines were mostly administered in the elderly. The fact that Health Care Workers, 
where women are more frequent than males, had priority for vaccination, may contribute to explain the 
female predominance, on  CVST after both COVID-19 vaccines. Given the small sample size and wide 
confidence intervals, no firm conclusions can be drawn from the mortality rate of CVST after mRNA 
vaccines.  
Our study has some strengths in comparison with previous reports of CVST after anti-SARS-CoV-2 
vaccines. It used a centralized European pharmacovigilance database that includes several hundreds of 
notified cases irrespective of the applied vaccine. This allowed us to describe CVST cases occurring after 
any type of vaccine, irrespective of platelet count values. We centrally reviewed not only cases reported as 
CVST, but also cases signalled as intracerebral haemorrhages or thrombocytopenia, who could have 
CVST as a secondary diagnosis. Additionally, we used a historical control group of CVST, registered in the 
International CVST consortium database in the last years before the COVID-19 pandemic. 
The study also has several limitations. First, the main purpose of the European pharmacovigilance 
database is to register and signal unexpected adverse events, not previously detected in the clinical trials 
that were used to register those vaccines. These notifications are often focused on the adverse effect and 
generally do not provide detailed clinical information necessary for further research on the topic, resulting in 
a large number of notifications with missing information and limiting the number of variables that can be 
analysed. Especially data on traditional risk factors and frequency of positive PF4 antibodies should be 
interpreted with caution. Second, despite the broadness of the EudraVigilance database, there is still a 
possibility of selective or underreporting, since there is no method to determine with certainty if all CVST 
cases that occurred after SARS-CoV-2 vaccination were notified to EMA.  Selective reporting could have 
also been influenced by the widespread media attention, particularly focused on the ChAdOx1 nCov-19 
vaccine.  Selective reporting of more severe cases is a possibility, whereas less severe cases might not 
have been diagnosed, recognized as an ADR or reported. Third, higher mortality in CVST vaccine 
associated cases, may be partly explained by less experience in managing CVST in centres notifying 
ADRs, in comparison with the three high-volume academic centres participating in the registry. Additionally, 
at the time of the inaugural reports of CVST after vaccination, there was limited experience in treating 
CVST with thrombocytopenia. Fourth, diagnosis and quality of information were not centrally validated, and 
thus accuracy of the diagnoses is unknown.  Fifth, we could not analyse CVST occurring after the 
Ad26.COV2.S vaccine, because no cases were reported in European countries during the study period. 
Finally, we did not calculate the absolute risk of CVST occurring after SARS-CoV-2 vaccination, as the 
detailed information on the denominator, namely the number of vaccinated Europeans by age and sex 
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Despite the robust information on the profile of CVST occurring after the different SARS-CoV-2 vaccines in 
the present study, further prospective registries with more detailed information on clinical, imaging and 
laboratory results and outcome are needed (14). 
In conclusion, analysis of the EMA pharmacovigilance database shows that CVST occurring after the 
ChAdOx1 nCov-19 vaccine has a clinical profile that is different from patients with CVST unrelated to 
vaccination. CVST after ChAdOx1 nCov-19 is associated with thrombocytopenia in approximately half of 
reported patients and has a high mortality rate. CVST cases occurring after mRNA vaccines were similar to 
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Tables 
Table 1. Comparison of CVST cases after ChAdOx1 nCov-19, mRNA vaccines and pre-COVID-
19 CVST cases from the International CVST Consortium  









Age categories    
Age 0-29 25/124 (20%) 1/22 (5%) 19/100 (19%) 
Age 30-59 78/124 (63%) 10/22 (45%) 62/100 (62%) 
Age ≥60  21/124 (17%) 11/22 (50%) 19/100 (19%) 
Female 138/184 (75%) 20/26 (77%) 66/100 (66%) 
Male 46/184 (25%) 6/26 (23%) 34/100 (34%) 
Any CVST risk factor reported
a
 20/187 (11%) 4/26 (15%) 64/100 (64%) 
Oral contraceptive use reported
b 


















COVID-19 PCR test performed
f 
39/187 (21%) 6/26 (23%) NA 






CVST: cerebral venous sinus thrombosis, VTE: venous thromboembolic events, PCR: polymerase 
chain reaction; 
a 
Risk factors included: cancer, hormone replacement therapy or oral contraceptive 
use, genetic thrombophilia, any concomitant infection; 
b 
Percentage of women under the age of 60; 
c
 




Concomitant VTEs: splanchnic 
vein thrombosis (n=11), pulmonary embolism (n=9), deep vein thrombosis (n=4), pelvic/renal vein 
thrombosis (n=3), vena cava thrombosis (n=1), retinal thrombosis (n=1), unknown (n=1). A total of 30 
VTEs reported in 22 patients. 
e 
For the control group we defined all VTEs occurring within a range of 
±30 days from the CVST symptom onset as concomitant VTEs; 
f 
COVID-19 PCR test performed 











Figure 1. Selection of CVST cases in the EudraVigilance database 
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